Cisplatin pharmacology

Author: pgru

August undefined, 2024

WebTherefore, the mechanism of cisplatin in promoting PD-L1 expression by YAP1 was investigated in the present study, and we found that cisplatin increased the expression level of YAP1 in the mouse liver with H22 cells. Meanwhile, cisplatin improved the expression level of PD-L1, IL-1β and CCL2 in the tumor microenvironment. WebFeb 25, 2024 · Cisplatin is one of the most effective chemotherapy drugs for ovarian cancer, but resistance is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in most advanced patients, final relapse and death are caused by acquired drug resistance.

Pharmaceutics Free Full-Text Pd (II) and Pt (II) Trinuclear ...

WebThe cardiotoxic effect of chemotherapeutic agents as cisplatin has become a major issue recently. Interference with mitochondrial dynamics, biogenesis, redox status, and apoptosis are the most possible underlying mechanisms. Semaglutide is a human glucagon-like peptide-1 receptor agonist (GLP-1R), w … WebSep 24, 2024 · Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, generating genetic and epigenetic changes that lead to the generation of resistance and the activation of intrinsic resistance mechanisms in cancer cells. Among them, we can find mutations, … ordering organic turkey

Cisplatin promotes the expression level of PD-L1 in the ...

WebTherapeutic efficacy of cisplatin-based treatment of late stage urothelial carcinoma (UC) is limited by chemoresistance. To elucidate underlying mechanisms and to develop new approaches for overcoming resistance, we generated long-term cisplatin treated (LTT) UC cell lines, characterised their cisplatin response, and determined the expression of … WebCisplatin / pharmacology* Cisplatin / therapeutic use DNA / drug effects Drug Resistance / genetics Gene Expression Regulation, Neoplastic / drug effects Humans Organoplatinum Compounds / pharmacology ... WebFeb 17, 2024 · Cisplatin infusion solutions at a concentration >0.5 mg/mL may result in tissue cellulitis, fibrosis, necrosis, pain, edema, and erythema. Gastrointestinal toxicity: [US Boxed Warning]: Cisplatin can cause severe nausea and vomiting; use highly effective antiemetic premedication. irf3 transcription factor

CISplatin Injection - Food and Drug Administration

WebCisplatin Cl2H6N2Pt CID 5460033 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more. National Institutes of Health. National Library of Medicine. National Center for Biotechnology Information. PubChem ... WebJul 17, 2024 · Cisplatin is a widely used chemotherapeutic agent that is clinically approved to fight both carcinomas and sarcomas. It has relatively high efficiency in treating ovarian cancers and metastatic testicular cancers. It is generally accepted that the major mechanism of cisplatin anti-cancer action is DNA damage. ordering original birth certificates onlineWebMar 28, 2024 · Cisplatin is a chemotherapeutic drug that has been used in the treatment of various types of human cancers such as ovarian, lung, … irf3205 mosfet datasheet pdf

"WebApr 10, 2024 · Triple-negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer and constitutes 10–20% of all breast cancer cases. Even though platinum-based drugs such as cisplatin and carboplatin are effective in TNBC patients, their toxicity and development of cancer drug resistance often hamper their clinical use. Hence, novel … " - Cisplatin pharmacology

Cisplatin pharmacology

Therapeutic strategies to overcome cisplatin resistance in

WebSep 18, 2024 · Cisplatin is a medication used to manage and treat solid tumors and hematologic malignancies. It is in the alkylating agent class of cytotoxic medications. This activity reviews the indications, action, and … WebCisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or …

Did you know?

WebOct 5, 2014 · Cisplatin is clinically proven to combat different types of cancers including sarcomas, cancers of soft tissue, bones, muscles, and blood vessels. … WebSep 15, 2024 · Platinum-based anticancer drugs (PADs), mainly cisplatin, carboplatin, and oxaliplatin, are widely used efficacious long-standing anticancer agents for treating several cancer types. However, clinicians worry about PAD chemotherapy and its induction of severe non-targeted organ toxicity. Compelling evidence has shown that toxicity of PAD …

WebJul 1, 2024 · Background/aim: Cisplatin combined with pemetrexed disodium heptahydrate (pemetrexed) is considered the standard treatment for patients with advanced, non-squamous, non-small-cell lung cancer. However, its growth-inhibitory effects on KRAS-dependent lung cancer as monotherapy and combination therapy are not well understood. WebCisplatin for injection has been administered at 75 mg/m. 2 . to 100 mg/m. intravenously per cycle once every 3 to 4 weeks on Day 1. Other doses and combination regimens have been used. 2.4 Advanced Bladder Cancer . Cisplatin for injection has been administered at 50 mg/m. 2 . to 70 mg/m. intravenously per cycle once every 3 to 4 weeks.

WebAug 18, 2024 · It describes a protein-protein interaction network that indicates highly dysregulated TP53, MDM2, and CDKN1A genes as they encode the top networking proteins that may be involved in cisplatin tolerance, these all being upregulated in … WebSep 15, 2024 · Cisplatin is the prototype platinum coordination complex classified as an alkylating agent and used intravenously in the treatment of several forms of cancer. Cisplatin has been associated with a low rate of serum enzyme elevations and with rare cases of clinically apparent, acute liver injury.

WebObjectives: Cisplatin-induced ototoxicity is a common permanent consequence of curative chemoradiation for locally advanced head and neck squamous cell carcinoma (HNSCC). Predictors of ototoxicity in HNSCC were examined. Materials and methods: In this prospective, observational cohort study, 206 adult HNSCC patients underwent …

WebCisplatin is a chemotherapy medication used to treat a number of cancers. [2] These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, … irf3 phosphorylation antibodyWebThe current accepted paradigm about cisplatin mechanism of action is that the drug induces its cytotoxic properties through binding to nuclear DNA and subsequent interference with normal transcription, and/or DNA replication mechanisms. irf3 phosphorylationWebJun 13, 2005 · Cisplatin is a platinum based chemotherapy agent used to treat various sarcomas, carcinomas, lymphomas, and germ cell tumors. Brand Names. Platinol. Generic Name. Cisplatin. DrugBank Accession Number. DB00515. Background. Cisplatin, cisplatinum or cis-diamminedichloroplatinum (II) (CDDP) is a platinum-based … ordering organic seeds onlineWebAim: To investigate the synergetic effect and the mechanism of antitumor action of the antibiotic lidamycin in combination with cisplatin in vitro. Methods: Cytotoxicity of the … irf3205pbf datasheetWebSep 1, 2024 · Cisplatin for injection, USP, a platinum-based drug for intravenous use, is a white to light yellow lyophilized powder. Each vial of Cisplatin for injection, USP … ordering original ford parts irf3205pbfWebCisplatin Pharmacology Cisplatin About Cisplatin Alkylating Agent, Platinum- Analog , Antineoplastic. Mechanism of Action of Cisplatin Cisplatin exerts its cytotoxic effect by … irf3205spbf-cn